Induction of a transient dysexecutive syndrome in Parkinson's disease using a subclinical dose of scopolamine

Behavioural Neurology

Volumn 11, Issue 4, 1998, Pages 187-195

  Bedard M A ^a,b   Lemay, S ^a   Gagnon, J F ^a   Masson, H ^b   Paquet, F ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Acetylcholine; Attention; Cognition; Executive functions; Frontal syndrome; Memory; Parkinson's disease; Scopolamine

Indexed keywords

BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; PERGOLIDE; SCOPOLAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN DYSFUNCTION; BRAIN INJURY; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; FRONTAL LOBE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0342656178     PISSN: 09534180     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/316598     Document Type: Article

References (58)

1. Y. Agid, F. Javoy-Agid and M. Ruberg, Biochemistry of neurotransmitters in Parkinson's Disease, in: Movement disorders II, C.D. Marsden and S. Fahn, eds, Butterworths & Co. Publishers, London, 1987, pp. 165-230.
2. Y. Agid, M. Ruberg, F. Javoy-Agid, E. Hirsch, R. Raisman-Vozari, S. Vyas, B. Faucheux, P. Michel, A. Kastner, V. Blanchard, P. Damier, J. Villares and P. Zhang, Are dopaminergic neurons selectively vulnerable to Parkinson's disease?, in: Advances in Neurology. Vol. 60, H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Misuno, eds, Raven Press, New-York, 1993, pp. 148-164.
3. G.E. Alexander, M.R. DeLong and P.L. Strick, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Annual Review of Neuroscience 9 (1986), 357-381.
4. M. Asahina, H. Shinotoh, K. Hirayama, K. Suhara, F. Shishido, O. Inoue and Y. Tateno, Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET, Acta Neurologica Scandinavica 91 (1995), 437-443.
5. J. Beardsley and F. Puletti, Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment, Archives of Neurology 25 (1971), 145-150.
6. M.A. Bédard, H. Masson, H. Perreault and S. Gaudreau, Specific memory deficits related to lesions of the cholinergic systems in Parkinson's disease, in: Dementia in Parkinson's disease, A.D. Korczyn, ed., Monduzzi Editore, Bologna, Italy, 1994, pp. 213-216.
7. 1 agonist, Clinical Neuropharmacology 21 (1998), 108-117.
8. R.G. Brown and C.D. Marsden, Internal versus external cues and the control of attention in Parkinson's disease, Brain 111 (1988), 323-345.
9. R.G. Brown and C.D. Marsden, Dual task performance and processing resources in normal subjects and patients with Parkinson's disease, Brain 114 (1991), 215-231.
10. J.A. Cooper, H.J. Sagar, S.M. Doherty, N. Jordan, P. Tidswell and E.V. Sullivan, Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease, Brain 115 (1992), 1701-1725.
11. J.L. Cummings, Subcortical Dementia, Oxford University Press, New-York, 1990.
12. J.C. Dalrymple-Alford, A.S. Kalders, R.D. Jones and R.W. Watson, A central executive deficit in patients with Parkinson's disease, Journal of Neurology, Neurosurgery and Psychiatry 57 (1994), 360-367.
13. B. Dubois, F. Danzé, B. Pillon, G. Cusimano, F. Lhermitte and Y. Agid, Cholinergic-dependent cognitive deficits in Parkinson's disease, Annals of Neurology 22 (1987), 26-30.
14. B. Dubois, B. Pillon, F. Lhermitte and Y. Agid, Cholinergic deficiency and frontal dysfunction in Parkinson's disease, Annals of Neurology 28 (1990), 117-121.
15. B. Dubois and B. Pillon, Biochemical correlates of cognitive changes and dementia in Parkinson's disease, in: Parkinson's disease: neurobehavioral aspects, S.J. Huber and J.L. Cumming, eds, Oxford University Press, Oxford, 1992, pp. 178-198.
16. N. Duchesne, M.A. Bédard, J.P. Soucy and H. Masson, Relationship between the deficit in sharing attention and the degree of striatal dopaminergic denervation in Parkinson's disease: A SPECT study using IODINE 123-B-CIT, Neurology 50 (1998), A44.
17. C. Duyckaerts, P. Gaspas, C. Costa, A.M. Bonnet and J.J. Hauw, Dementia in Parkinson's disease - Morphometric data, in: Advances in Neurology, Vol. 60, H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Misuno, eds, Raven Press, New-York, 1993, pp. 447-455.
18. M.F. Folstein, S.E. Folstein and P.R. McHugh, Mini-mental state: a practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research 12 (1975), 189-198.
19. R.B. Godwin-Austen, E.B. Tomlinson, C.C. Frears and H.W.L. Kok, Effects of L-Dopa in Parkinson's disease, Lancet ii (1969), 165-168.
20. P.S. Goldman-Rakic, Circuitry of the primate prefrontal cortex and the regulation of behavior by representational memory, in: Handbook of physiology: The nervous system, higher functions of the brain. Section 1, Vol. V (part 1), F. Plum, ed., American Physiology Society, Bethesda, 1987, pp. 373-417.
21. A.M. Gotham, R.G. Brown and C.D. Marsden, 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa, Brain 111 (1988), 299-321.
22. E. Grober and H. Buschke, Genuine memory deficits in dementia, Developmental Neuropsychology 3 (1987), 13-36.
23. E. Grober, H. Buschke, M.D. Crystal, M.A. Bang and R. Dresner, Screening for dementia by memory testing, Neurology 38 (1988), 900-903.
24. E. Grober, R.M. Leipzig, R.B. Lipton, W. Wisniewski, M. Schroeder, P. Davies, W. Ritier and H. Buschke, Does scopolamine directly impair memory?, Journal of Cognitive Neurosciences 1 (1989); 329-335.
25. E. Hirsch, A.M. Graybiel, C. Duyckaerts and F. Javoy-Agid, Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson's disease and in Progressive Supranuclear Palsy, Proceedings of the National Academy of Sciences 84 (1987), 5976-5980.
26. M.M. Hoehn and M.D. Yahr, Parkinsonism: onset, progression and mortality, Neurology 17 (1967), 427-442.
27. O. Homykiewicz, Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms, in: Advances in Neurology, Vol. 60, H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Misuno, eds, Raven Press, New-York, 1993, pp. 140-147.
28. S.J. Huber, H.G. Shulman, G.W. Paulson and E.C. Shuttleworth, Fluctuations in plasma dopamine level impair memory in Parkinson's disease, Neurology 37 (1989), 1371-1375.
29. F. Javoy-Agid and Y. Agid, Is the mesocortical dopaminergic system involved in Parkinson's disease?, Neurology 30 (1980), 1326-1330.
30. K. Jellinger, The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease, Journal of Neurology, Neurosurgery and Psychiatry 51 (1988), 540-543.
31. K.W. Lange, T.W. Robbins, C.D. Marsden, M. James, A.M. Owens and G.M. Paul, L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction, Psychopharmacology Berlin 107(2-3) (1992), 394-404.
32. M. Lezak, Neuropsychological assessement, 3rd ed, Oxford, New-York, 1995.
33. A.W. Loranger, H. Goodell, J.E. Le and F. McDowell, Levodopa treatment of Parkinson's syndrome improve intellectual functioning, Archives of General Psychiatry 26 (1972), 163-168.
34. C. Malapani, B. Pillon, B. Dubois and Y. Agid, Impaired simultaneous cognitive task performance in Parkinson's disease: A dopamine-related function, Neurology 44 (1994), 319-326.
35. C. Malapani, B. Rakatin, R. Levy, W.H. Meck, B. Deweer, B. Dubois and J. Gibbon, Coupled temporal memories in Parkinson's disease: A dopamine-related dysfunction, Journal of Cognitive Neuroscience 10 (1998), 316-331.
36. S. Mattis, Mental status examination for organic mental syndrome in the elderly patient, in: Geriatric Psychiatry, L. Bellak and T.B. Karasu, eds, Grune & Stratton, New York, 1976, pp. 77-121.
37. E. Mohr, G. Fabbrini, J. Williams, J. Schlegel, C. Cox, P. Fedio and T.N. Chase, Dopamine and memory function in Parkinson's disease, Movement Disorders 4(2) (1989), 113-120.
38. D.A. Norman and T. Shallice, Attention to action: willed and automatic control of behaviour, University of California CHIP Report 99, 1980.
39. M. Petrides and B. Milner, Deficits on subject-ordered tasks after frontal and temporal lobe lesions in man, Neuropsychologia 20 (1982), 249-262.
40. B. Pillon, B. Dubois, A.M. Bonnet, M. Esteguy, J. Guimaraes, J.M. Vigouret, F. Lhermitte and Y. Agid, Cognitive 'slowing' in Parkinson's disease fails to respond to levodopa treatment: the 'Fifteen objects test', Neurology 39 (1989a), 762-768.
41. B. Pillon, B. Dubois, G. Cusimano, A. Bonnet, F. Lhermitte and Y. Agid, Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?, Journal of Neurology, Neurosurgery, and Psychiatry 52 (1989b), 201-206.
42. B. Pillon, B. Deweer, Y. Agid and B. Dubois, Explicit memory in Alzheimer's, Huntington's and Parkinson's diseases, Archives of Neurology 50 (1993), 374-379.
43. B. Pillon, N. Gouider-Khouja, B. Deweer, M. Vidailhet, C. Malapani, B. Dubois and Y. Agid, Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy, Journal of Neurology, Neurosurgery, and Psychiatry 58 (1995), 174-179.
44. M.I. Posner, Orienting of attention, Quaterly Journal of Experimental, Psychology 32 (1980), 3-25.
45. J.M. Rabey, M.Y. Neufeld, T.A. Treves, P. Sifris and A.D. Korczyn, Cognitive effects of scopolamine in dementia, Journal of Neural Transmission: General section 103 (1996), 873-881.
46. M. Ruberg, F. Rieger, A. Villageois, A.M. Bonnet and Y. Agid, Acetylcholinesterase and butylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease, Brain Research 362 (1986), 83-91.
47. J.S. Schneider and C.J. Kovelowski, Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys, Brain Research 519 (1990), 122-128.
48. T. Shallice, Specific impairments of planning, Philosophical transactions of the Royal Society of London B 298 (1982), 199-209.
49. K.M. Shaw, A.J. Lees and G.M. Stern, The impact of treatment with levodopa on Parkinson's disease, Quaterly Journal of Medicine 49 (1980), 283-293.
50. T. Sunderland, P.N. Tariot, R.M. Cohen, H. Weingartner, E.A. Mueller and D.L. Murphy, Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls, Archives of General Psychiatry 44 (1987), 418-126.
51. A.E. Taylor, J.A. Saint-Cyr and A.E. Lang, Frontal lobe dysfunction in Parkinson's disease, Brain 109 (1986), 845-883.
52. A.E. Taylor, J.A. Saint-Cyr and A.E. Lang, Parkinson's disease: cognitive changes in relation to treatment response, Brain 110 (1987), 35-51.
53. A.E. Taylor and J.A. Saint-Cyr, The neuropsychology of Parkinson's disease, Brain and Cognition 28 (1995), 281-296.
54. K.P.M. Van Spaendonck, H.J.C. Berger, M.W.I. Horstink, E.L. Buytenhuijs and A.R. Cools, Impaired cognitive shifting in Parkinsonian patients on anticholinergic therapy, Neuropsychologia 31 (1993), 407-411.
55. B.H. Wainer and M.M. Mesulam, Ascending cholinergic pathways in the rat brain, in: Brain Cholinergic Systems, M. Steriade and D. Biesold, eds, Oxford University Press, Oxford, 1990, pp. 65-199.
56. H. Weingartner, S. Burns, R. Diebel and P.A. LeWitt, Cognitive impairments in Parkinson's disease: distinguishing between effort-demanding and automatic cognitive processes, Psychiatry Research 11 (1984), 223-235.
57. K.A. Wesnes and P.M. Simpson, Can scopolamine produce a model of the memory deficits seen in aging and dementia?, in: Practical aspects of memory: current research and issues, M.M. Gruneberg, P.E. Morris and R.N. Sykes, eds, John Wiley, New York, 1988.
58. R.M. Zweig, W.R. Jankel, J.C. Hedreen, R. Mayeux and D.L. Price, The pedunculopontine nucleus in Parkinson's disease, Annals of Neurology 26 (1989), 41-46.